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Board of Visitors hears reports on issues 
and research during annual meeting 
The Board of Visitors held its annual meeting in June at the 
School of Medicine. Activities during the day-long event in-
cluded faculty presentations, business reports and a luncheon at-
tended by Board members and BUSM students. 
During the morning session. Board members heard from Sel-
wyn Broitman, Ph.D., assistant dean for admissions, who spoke 
on BUSM's admissions process. Barry Manuel, M.D., an as-
sociate dean for continuing medical education, and Alan Sager, 
Ph.D., an associate professor of Public Health, presented "What 
Are the Problems of Massachusetts Physicians—^and How to 
Solve Them?" Richard H. Egdahl, M.D., director of the Medical 
Center, addressed the Board members on "The Residency Con-
troversy—Can the Private Sector Do the Job?" 
Speakers during the afternoon session included Aubrey 
Milunsky, M.D., D.Sc, director of BUSM's Human Genetics 
Center, who presented research on "The New Frontiers in the 
Diagnosis and Treatment of Genetic Disorders." Carl Franzblau, 
Ph.D., an associate dean for graduate biomedical science studies, 
spoke on "Technology Transfer: Liaison with Industry." Other 
speakers included Dean Aram V. Chobanian; Betty Russell, 
director of media relations; Herbert Tobin, director of develop-
ment; and Betsy Stengel, director of government liaison. 
Study links rise in heart disease in 
developing countries to urbanization 
A pilot study conducted by BUSM researchers links urbaniza-
tion with the increase of cardiovascular disease in developing 
countries. BUSM researchers, working in conjunction with the 
Andean Foundation for Biopathologic Studies and the Univer-
sity of Massachusetts, studied 191 people who lived in three dif-
ferent degrees of urbanization in Ecuador—rural, town and 
city—to evaluate the influence of lifestyle on known risk factors 
for cardiovascular disease, including obesity, high blood pres-
sure, elevated blood cholesterol and cigarette smoking. 
Researchers, led by principal investigator Juan C. Zevallos, 
M.D., a BUSM instructor of medicine, appointment pending, 
found that those living in urban areas smoked more, were 
heavier and had higher blood pressure and cholesterol levels. 
They also noted that people adopting a more urban lifestyle in 
Ecuador are becoming less active, are eating more prepared and 
fast foods that contain more fat, and are developing the same 
bad lifestyle habits that made cardiovascular disease so 
prevalent in the United States. 
BUSM researchers and the Andean Foundation are planning 
longer-term studies to continue to evaluate the problem and to 
BOARD OF VISITORS LUNCHEON—Elihu Rose, Ph.D., left, a 
member and former chairman of the Board of Visitors, chats with 
Fred Mamuya, a BUSM student, during the Board of Visitors lunch-
eon. The luncheon gave the Board members an opportunity to 
mingle with BUSM students and faculty. (Photo by Gus Freedman) 
develop ways to prevent cardiovascular disease from becoming 
as widespread in developing countries as it is in the United 
States. 
1989-1990 Whitaker Fund Awards 
announced for joint research 
The Whitaker Health Sciences Fund has awarded ten $48,000 
grants to BUSM Junior faculty members collaborating on re-
search with Massachusetts Institute of Technology faculty mem-
bers in the biomedical area. The Fund awarded a total of 
$600,000 in research grants, effective July 1, to BUSM. 
School of Medicine recipients of the Whitaker awards for the 
1989-90 fiscal year are: Deborah E. Dobson, Ph.D., an assistant 
professor of biochemistry; John R. Duguid, M.D., an assistant 
professor of neurology; Gyorgy Frendl, M.D., an instructor of 
medicine, appointment pending; Dharma R. Kodali, Ph.D., an in-
structor of biophysics; David M. Larson, Ph.D., an assistant 
professor of pathology; Nadia A. Rosenthal, Ph.D., an assistant 
professor of biochemistry; Bruce J. Schnapp, Ph.D., a research 
associate professor of physiology; Charles Seymour, Ph.D., an 
assistant professor of microbiology; Kathy K. Svoboda, Ph.D., 
an assistant professor of anatomy; and Ken S. Zaner, M.D., an 
assistant professor of medicine, appointment pending. 
2 
A low-fat breakfast can reduce 
total fat and cholesterol intake 
A simple change in typical breakfast foods can reduce sig-
nificantly total fat and cholesterol intake and potentially 
decrease blood cholesterol levels that contribute to coronary 
heart disease, according to a study by R. Curtis Ellison, M.D., 
chief of the Section of Preventive Medicine and Epidemiology 
and a professor of medicine. 
Ellison studied 98 college students to determine the effects of 
changing from a high-fat to a low-fat breakfast. After the 
students' blood cholesterol baselines were determined, they 
were randomly assigned to either a high-fat breakfast with 
choices including eggs, bacon, pancakes and whole milk, or a 
low-fat diet of cereals, muffins, fresh fruits and low-fat milk. 
They followed one of the two diets for three weeks and then 
switched to the other menu for another three weeks. The stu-
dents continued to consume their usual diets—including fast 
foods and other high-fat foods—for the remainder of the day. 
Results of the study indicate that when students decreased 
their fat intake at breakfast, they achieved significant reductions 
in total daily intakes of both fat and cholesterol. For example, 
compared to a high-fat breakfast, a low-fat breakfast reduced 
breakfast-fat intake by 50 percent and resulted in a 15-percent 
reduction of total daily fat. Cholesterol intake at breakfast was 
79 percent less during the low-fat period than during the high-fat 
period. Fat and cholesterol reductions achieved at breakfast 
were not compensated for by increased fat intake later in the 
day. The low-fat breakfast also had a small yet significant effect 
on students' blood cholesterol levels, especially among those 
whose cholesterol was above average. 
The results of the study were presented in June at the Second 
International Conference on Preventive Cardiology in 
Washington, D.C. 
Low-yield cigarettes pose same risk 
for heart attacks as high-yield type 
Smoking cigarettes low in nicotine and carbon monoxide rather 
than "high-yield" cigarettes does not reduce the risk of first, non-
fatal heart attacks in women, according to a study conducted by 
researchers at BUSM's Slone Epidemiology Unit. Julie Palmer, 
Sc.D., an assistant professor of public health (epidemiology and 
biostatics) and an epidemiologist at the Slone Epidemiology 
Unit, was the principal investigator for the study published in 
the June 15th issue of the. New England Journal of Medicine. 
In the case-control study. Palmer and other researchers 
evaluated more than 3,000 women to determine if smoking low-
yield cigarettes reduced the risk of myocardial infarction in 
women under the age of 65. The study focused on women for 
several reasons: cigarette smoking is an important risk factor of 
coronary heart disease in women, as it is in men; while there has 
been considerable progress in reducing the prevalence of men 
who smoke, the decline in women has been less dramatic; and 
women are more likely than men to smoke low-yield cigarettes. 
The BUSM researchers found the risk of heart attack for 
women who smoked the lowest-yield cigarettes was as high as it 
was for women who smoked the highest-yield cigarettes. The re-
searchers also suggested that one reason the proportion of 
women who have quit smoking is significantly less than the 
proportion of men who have quit is that rather than quit, women 
may have switched to low-yield cigarettes. According to Pal-
mer, "The study indicates that women should think about quit-
ting smoking altogether rather than switching brands." 
Antivomiting drug promises to improve 
quality of life for cancer patients 
A new antivomiting (antiemetic) drug may offer a better quality 
of life and a better treatment outcome for many cancer patients, 
according to a nationwide study led by Paul Hesketh, M.D., an 
assistant professor of medicine. The study, published in the 
June Journal of Clinical Oncology, showed ondansetron to be 
75-percent effective in preventing chemotherapy-induced vomit-
ing without the adverse side effects of traditional medications. 
Ondansetron is among a new class of drugs, called seratonin 
antagonists, which block nerve impulses in the bowel and/or 
brain that trigger nausea and vomiting. The drug does not cause 
the severe neurological side effects of other commonly used an-
tivomiting agents, effects such as extreme drowsiness, agitation 
and involuntary movement. 
In Hesketh's study, 85 cancer patients on high-dose cisplatin 
therapy (a common and highly emetogenic drug used in 
xhemotherapyyreceived three doses of ondansetron intravenous-
ly either every six or every eight hours, beginning 30 minutes 
before the chemotherapy session. Patients were then evaluated 
over 24 hours for retching or vomiting episodes and were asked 
to indicate their degree of nausea before and after chemotherapy. 
Fifty-five percent had no episodes and reported feeling no 
nausea; twenty percent had only one or two episodes. No dif-
ferences were found between the eight- and six-hour schedules. 
Although a few patients had mild headaches or slight temporary 
liver changes, none experienced the more severe side effects of 
traditional medications. 
"While this drug will not cure cancer, it may significantly 
contribute to the success of treatment, since it will increase the 
likelihood that patients will adhere to their treatment plan," says 
Hesketh. 
BUSM study looks at causes, 
treatment of impotence in diabetic men 
A recent BUSM study provided the first evidence of functional 
impairment of erectile tissue in males with diabetes. The re-
search results show that diabetes damages nerves and cells that 
line blood-vessel walls in men. In this study funded by the Na-
tional Institutes of Health, BUSM researchers followed 63 
patients with erectile difficulties; 21 (33 percent) of the patients 
had histories of diabetes. The results of experiments 
demonstrate that diabetes impairs the nerve and endothelial 
mechanisms that mediate the relaxation of the smooth muscle of 
the penis—^a condition necessary for an erection to occur—but 
does not impair the function of die muscle. This finding led re-
searchers to conclude that injecting vasodilators direcdy into the 
penis is a rational form of therapy for diabetic impotent patients. 
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RETIRING AT AGE OF 80—Members of SPH's faculty and staff 
gather around Margaret Scott (second row, second from left) who 
retired this year at the age of 80. Ms. Scott, who had originally 
retired at the age of 65, re-entered the workforce ten years ago 
when SPH was founded as a secretary in the Admissions Office. 
(Photo by David Keough, Educational Media Support Center) 
Inigo Saenz de Tejada, M.D., an assistant research professor 
of urology and director of the urology laboratory at BUSM, was 
the principal investigator of the study . Richard A. Cohen, 
M.D., an associate profesor of medicine and an assistant profes-
sor of physiology, was the senior author of the paper which was 
published in the New England Journal of Medicine. 
Ryser is awarded ACS research grant 
Hughes J.-P. Ryser, M.D., Ph.D., a professor of pathology, 
recently was awarded a three-year, $319,000 research grant from 
the American Cancer Society (ACS) to support his study of the 
cellular uptake of macromolecules. Entitled "Activation of En-
docytosed Drug Carriers," Ryser's research project will provide 
the foundation for optimal clinical use of anti-cancer im-
munotoxins. The award resulted from a nationwide competition 
and was based on the recommendations of the ACS peer review 
advisory committees, the Council for Research and Clinical In-
vestigation Awards and the Research and Clinical Investigation 
Committee of the National Board of Directors. 
Faculty member receives Glaxo grant 
Bruce Pearce, Ph.D., an assistant professor of pharmacology and 
experimental therapeutics, has been named by Glaxo, Inc., to 
participate in the Cardiovascular Discovery Grants program. 
Pearce will receive $254,000 over a three-year period from 
Glaxo. With the grant, Pearce will continue to study substance 
b, a neuroactive compound he discovered as a postdoctoral fel-
low. According to Pedro Cuatrecasas, M.D., Glaxo's senior vice 
president for research, the Discovery program of research for 
therapeutic agents will complement much of the basic research 
being funded by the National Institutes of Health. 
Cohen is elected president of AFCR 
Richard A. Cohen, M.D., an associate professor of medicine and 
an assistant professor of physiology, recently was elected presi-
dent of the American Federation of Clinical Research (AFCR), a 
national organization representing more than 12,000 clinical and 
basic research scientists. A member of the AFCR for four years, 
Cohen served as its secretary/treasurer for the past year. Cohen 
also is a member of the Peripheral Vascular Section of the 
department of medicine at UH and serves on the editorial boards 
of the American Journal of Physiology and Heart and Cir-
culatory Physiology. He will serve as president-elect of AFCR 
for the next year before beginning his one-year term as president. 
The MSMR: supporting animal research 
Educating the public and the legislature about biomedical re-
search, including the need for animal experimentation and how 
it contributes to the health and safety of humans and animals, is 
the purpose of the Massachusetts Society for Medical Research 
(MSMR). 
According to Anneliz Hannan, executive director of the 
MSMR, animal-rights activism is on the rise and is currently 
having a detrimental impact on research at federal, state and 
local levels of government. "The animal controversy is one of 
the major poHtical issues facing biomedicine. It is driven by ac-
tive opposition and emotion, yet is presented to the public and 
legislature as a 'moral' crisis," said Hannan. 
Both BUSM and the University Hospital have been substan-
tial institutional contributors to the MSMR since 1984. How-
ever, the society's success will depend greatly upon the financial 
support and participation from all individuals who benefit from 
biomedical research, according to Hannan. For more informa-
tion about the MSMR, caU (617) 891-4544. 
ACS research grants available 
The Hubert H. Humphrey Cancer Research Center has been 
awarded an Institutional Grant from the National Chapter of the 
American Cancer Society (ACS) to encourage young inves-
tigators (junior faculty, post-docs) to carry out cancer-related re-
search. 
The grant program's primary purpose is to serve as "seed" 
money to permit initiation of promising new projects or novel 
ideas that will serve as basis for future grant applications from 
other programs. The awards will vary according to the needs of 
the investigator and should not exceed $6,0(X). The majority of 
allocations will be made to persons who have not received prior 
grant support. 
Applications will be awarded on a competitive basis and 
evaluated according to criteria described in the application 
forms. Application forms are available from the Cancer Re-
search Center office. School of Medicine, K701,638-4173 
(x4173). The deadline for applications is October 2,1989. 
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Menzoian named professor of surgery 
James O. Menzoian, M.D., chief of the Section of Vascular 
Surgery at BUSM, recently was appointed a professor of surgery 
in BUSM's Department of Surgery. He also is director of the 
Vascular Fellowship Training Program and the Surgical Train-
ing Program at BUSM. Menzoian has been a member of the 
BUSM faculty and an attending surgeon at the University Hospi-
tal since 1976. 
Walsh elected to SOT position 
Carol T. Walsh, Ph.D., an associate professor of pharmacology 
and experimental therapeutics, recently was elected 
secretary/treasurer of the Metals Section of the Society of 
Toxicology (S.O.T.). She also serves as secretary/treasurer of 
the Northeast Chapter of S.O.T. During the spring semester, 
Walsh lectured on the toxicity of metals for courses at BUSM 
(Principles of Toxicology), Harvard School of Public Health (In-
dustrial Toxicology) and the Summer Institute of UMass-Har-
vard Education Resource Center (Occupational Toxicology). 
The semiannual chapter meeting of S.O.T. was held on June 
16 in the Hiebert Lounge of the Instructional Building. Topics 
discussed included the immunotoxicologic effects of metals, 
gene regulation by mercury and the significance to bacterial 
detoxification of mercurial compounds, and findings on the 
mutagenicity of nickel compounds. 
BUSM faculty member co-edits textbook 
Sami J. Harawi, M.D., an assistant professor of pathology and 
dermatology, helped write and edit a recently published 
textbook on the pathology of AIDS. The multi-authored book, 
published by Chapman and Hall, contains a number of chapters 
written by BUSM faculty. Titled "Pathology and Pathophysiol-
ogy of AIDS and HIV-Related diseases," the book promotes un-
derstanding a disease process on the cellular and tissue level in 
order to gain a clearer perception of the clinical manifestations 
of that disease. 
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